Summary
Seven of eight hypertensive Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria completed a randomised crossover trial to compare the renal effects of angiotensin converting enzyme inhibitor (enalapril) and calcium antagonist (nicardipine). Four-week fixed oral maintenance dosages of enalapril (10–20 mg/day) and nicardipine (60–120 mg/day) significantly (p<0.05) lowered the systolic and diastolic blood pressures without altering renal blood flow, glomerular filtration rate and filtration fraction. Both drugs significantly reduced (p<0.05) urinary albumin excretion rate and fractional clearance of albumin to similar extents. Total renal vascular resistance decreased significantly by nicardipine (p<0.05) and non-significantly by enalapril. Plasma osmotic pressure, plasma aldosterone concentration, total serum protein concentration, serum electrolytes and HbA1c remained unchanged by these drugs, whereas plasma renin activity was significantly higher (p<0.05) in the enalapril than in the control and nicardipine phases. These results suggest that both drugs have similar renal function preserving effects with a concomitant hypotensive action in hypertensive Type 2 diabetic patients with microalbuminuria, and that the angiotensin converting enzyme inhibitor may not have advantageous renal effects when compared to the calcium antagonist and vice versa. Both drugs might be useful for treatment of high blood pressure in hypertensive diabetic patients, if long-term studies of these drugs can be shown to benefit the patients over other conventional antihypertensive therapies.
Article PDF
Similar content being viewed by others
References
The Working Group on Hypertension in Diabetes (1987) Statement on hypertension in diabetes. Diabetes Care 10: 764–776
Pell S, D'Alonzo CA (1967) Some aspects of hypertension in diabets mellitus. J Am Med Assoc 202: 104–110
Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 285: 685–688
Parving H-H, Andersen AR, Smidt UM, Svendsen PAa (1983) Early and aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet I: 1175–1178
Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Sevendsen PA (1987) Effect of antihypertensive treatment on kidney functionin diabetic nephropathy. Br Med J 294: 1143–1447
Hommel E, Parving H-H, Mathiesen E, Edsbert B, Nielsen MD, Giese J (1986) Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 293: 467–470
Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M (1986) Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293: 471–474
Passa P, LeBlanc H, Marre M (1987) Effects of enalapril in insulin-dependent diabetic subjects with mild to moderate uncomplicated hypertension. Diabetes Care 10: 200–204
Marre M, LeBlanc H, Suarez L, Guyenne T, Ménard J, Passa P (1987) Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 294: 1448–1452
Jarret RJ (1984) The epidemiology of coronary heart disease and related factors in the context of diabetes mellitus and impaired glucose tolerance. In: Jarrett RJ (ed) Diabetes and heart disease. Elsevier, Amsterdam, pp 1–23
Khan MIG (1985) Manual of cardiac drug therapy. Bailliére Tindall, Eastbourne, pp 1–33
Pedrinelli R, Fouad FM, Tarazi RC, Bravo EL, Textor SC (1986) Nitrendipine, a calcium-entry blocker: renal and humoral effects in human arterial hypertension. Arch Intern Med 146: 62–65
Sunderrajan S, Reams G, Bauer JH (1987) Long-term renal effects of diltiazem in essential hypertension. Am Heart J 114: 383–388
Baba T, Ishizaki T, Murabayashi S, Aoyagi K, Tamasawa N, Takebe K (1987) Multiple oral doses of nicardipine, a calcium-entry blocker: effects on renal function, plasma renin activity, and aldosterone concentration in mild-to-moderate essential hypertension. Clin Pharmacol Ther 42: 232–239
Reams G, Hamory A, Lau A, Bauer JH (1988) Effect of nifedipine on renal function in patients with essential hypertension. Hypertension 11: 452–456
Baba T, Boku A, Ishizaki T, Sone K, Takebe K (1986) Renal effects of nicardipine in patients with mild-to-moderate essential hypertension. Am Heart J 111: 552–557
Mogensen CE, Christensen CK (1980) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89–93
Houston MC (1981) Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 102: 415–430
Jackson G, Harry JD, Robinson C, Kitson D, Jewitt E (1978) Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol. Br Heart J 40: 998–1004
van Schalk BAM, Geyskes GG, Kettner N, Boer P, Mees EJD (1986) Comparison of enalapril and propranolol in essential hypertension. Eur J Clin Pharmacol 29: 511–516
Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Silke B (1985) Anti-hypertensive dose-response effects of nicardipine in stable essential hypertension. Br J Clin Pharmacol 20: 135S-138S
Baba T, Ishizaki T, Ido Y, Aoyagi K, Murabayashi S, Takebe K (1986) Renal effects of nicardipine, a calcium entry blocker, in hypertensive Type II diabetic patients with nephropathy. Diabetes 35: 1206–1214
Willassen Y, Ofstad J (1983) Intrarenal pressure and sodium excretion in hypertension of chronic glomerulonephritis in humans. Hypertension 5: 375–384
Haber E, Koerner T, Page LB, Klinman B, Purnode A (1969) Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 29: 1349–1355
Ogihara T, Iinuma K, Nishi K, Arakawa Y, Takagi A, Kurata K, Miyai K, Kumahara Y (1977) A non-chromatographic non-extraction radioimmunoassay for serum aldosterone. J Clin Endocrinol Metab 45: 726–731
Miles DW, Mogensen CE, Gundersen HJG (1979) Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest 26: 5–11
Davis JE, McDonald JM, Jarrett L (1978) A high-performance liquid chromatography method for hemoglobin A1c. Diabetes 27: 102–107
Mercier DE, Feld RD, Witte DL (1978) Comparison of dew-point and freezing point osmometry. Am J Med Tech 44: 1066–1069
Resnick LM, Nicholson JP, Laragh JH (1987) Calcium, the renin-aldosterone system, and the hypotensive response to nifedipine. Hypertension 10: 254–258
Faris I, Agerskov K, Henrikson O, Lassen NA, Parving H-H (1982) Decreased distensibility of a passive vascular bed in diabetes mellitus: an indicator of microangiopathy? Diabetologia 23: 411–414
Simon G, Morioka S, Snyder DK, Cohn JN (1983) Increased renal plasma flow in long-term enalapril treatment of hypertension. Clin Pharmacol Ther 34: 459–465
O'Connor DT, Mosley CA, Cervenka J, Bernstein KN (1984) Contrasting renal haemodynamic responses to the angiotensin converting enzyme inhibitor enalapril and the beta-adrenergic antagonist metoprolol in essential hypertension. J Hypertension [Suppl 2]: 89–92
Christensen C, Mogensen CE (1985) Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 7 [Suppl II]: 109–113
Wiseman MJ, Bognetti E, Dodds R, Keen H, Viberti GC (1987) Changes in renal function in response to protein restricted diet in Type 1 (insulin-dependent) diabetic patients. Diabetologia 30: 154–159
Kupin WL, Cortes P, Dumler F, Feldkamp CS, Lilates MC, Levin NW (1987) Effect on renal function of changes from high to moderate protein intake in Type 1 diabetic patients. Diabetes 36: 73–79
Mogensen CE (1971) Urinary albumin excretion in early and long-term juvenile diabetes. Scand J Clin Lab Invest 28: 183–193
Viberti GC, Jarrett RJ, McCartney M, Keen H (1978) Increased glomerular permeability to albumin induced by exercise in diabetic subjects. Diabetologia 14: 293–300
Mattock MB, Keen H, Viberti GC, El-Gohari MR, Murrells TJ, Scott GS, Wing JR, Jackson PG (1988) Coronary heart disease and urinary albumin excretion rate in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 31: 82–87
Mühlhauser I, Bruckner J, Howorka K (1987) Near-normoglycaemia and microvascular complications. Diabetologia 30: 47–48
Parving H-H, Andersen AR, Hommel E, Smidt U (1985) Effects of longterm antihypertensive treatment on kidney function in diabetic nephropathy. Hypertension 7 [Suppl II]: 114–117
Parving H-H, Hommel E, Smidt UM (1988) Angiotensin converting enzyme inhibitor protects kidney function and reduces albuminuria in diabetic nephropathy. Diabetologia 31: 530A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baba, T., Murabayashi, S. & Takebe, K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia 32, 40–44 (1989). https://doi.org/10.1007/BF00265402
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00265402